Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01090921 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
A Phase 2 study, sponsored by Boston VA Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT01090921: Completed Phase 2 study, sponsored by Boston VA Research Institute.
NCT01090921 is a Phase 2 study that has completed, run by Boston VA Research Institute. The registered enrollment target is 50 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01090921, a Phase 2 study, has completed, sponsored by Boston VA Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
This is a research study to see if a new drug called bortezomib is useful to treat multiple myeloma in people who are newly diagnosed, and have not yet received treatment for their disease. VELCADE® (bortezomib) for Injection is a drug under development by Millennium Pharmaceuticals, Inc.
Primary Outcome
To evaluate the response rate for weekly administered bortezomib + dexamethasone in patients with newly diagnosed multiple myeloma who are ineligible for transplant or who are eligible but wish to postpone autologous stem cell transplant.
Interventions
- DRUG Bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2007-05 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
What the finished NCT01090921 record still lists
NCT01090921 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 1 intervention - of which Bortezomib is the first listed.
NCT01090921 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01090921 about?
NCT01090921 is a clinical study titled "Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma". This is a research study to see if a new drug called bortezomib is useful to treat multiple myeloma in people who are newly diagnosed, and have not yet received treatment for their disease. VELCADE® (bortezomib) for Injection is a drug under development by Millennium Pharmaceuticals, Inc.
What is the current status of trial NCT01090921?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2007-05. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01090921?
The interventions under investigation include: Bortezomib (DRUG).
Who is sponsoring clinical trial NCT01090921?
This trial is sponsored by Boston VA Research Institute, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01090921's enrollment target sits among peer trials
50 1195th of 2000 higher than 740 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia